UTHR Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
UTHR passed our risk checks.
United Therapeutics Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$276.26 |
52 Week High | US$279.98 |
52 Week Low | US$208.62 |
Beta | 0.54 |
1 Month Change | 5.28% |
3 Month Change | 20.21% |
1 Year Change | 26.22% |
3 Year Change | 57.06% |
5 Year Change | 233.53% |
Change since IPO | 4,433.50% |
Recent News & Updates
United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Recent updates
United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06Shareholder Returns
UTHR | US Biotechs | US Market | |
---|---|---|---|
7D | 1.2% | -0.4% | -0.6% |
1Y | 26.2% | 5.4% | 22.5% |
Return vs Industry: UTHR exceeded the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: UTHR exceeded the US Market which returned 22.5% over the past year.
Price Volatility
UTHR volatility | |
---|---|
UTHR Average Weekly Movement | 4.2% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: UTHR has not had significant price volatility in the past 3 months.
Volatility Over Time: UTHR's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
UTHR fundamental statistics | |
---|---|
Market cap | US$12.21b |
Earnings (TTM) | US$1.05b |
Revenue (TTM) | US$2.50b |
11.7x
P/E Ratio4.9x
P/S RatioIs UTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UTHR income statement (TTM) | |
---|---|
Revenue | US$2.50b |
Cost of Revenue | US$278.10m |
Gross Profit | US$2.22b |
Other Expenses | US$1.17b |
Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 23.68 |
Gross Margin | 88.87% |
Net Profit Margin | 42.05% |
Debt/Equity Ratio | 11.2% |
How did UTHR perform over the long term?
See historical performance and comparison